Autologous/syngeneic stem cell transplantation to treat refractory GvHD

Passweg, J. R.; Orchard, K.; Buergi, A.; Gratwohl, A.; Powles, R.; Goldman, J.; Apperley, J.; Mehta, J.
December 2004
Bone Marrow Transplantation;Dec2004, Vol. 34 Issue 11, p995
Academic Journal
Summary:Severe graft-versus-host disease (GvHD) refractory to corticosteroids responds poorly to experimental treatment and is often fatal. Attempts have been made to‘rescue’such patients by transfusing autologous cells in order to ablate the lymphoid component of the graft or to introduce regulatory cells capable of suppressing the GvHD. Here, we report details of eight patients with severe grade III-IV acute GvHD (n=7) or extensive chronic GvHD (n=1) who after failing a median of four lines of treatment were then treated with either autologous or syngeneic nucleated cell transfusions. Patients received standard conditioning (n=3), low intensity (n=2) or no conditioning (n=3) before the rescue procedure. In four of the five patients who received some form of conditioning, mixed chimerism or complete recipient hematopoiesis was restored. The GvHD resolved in four patients, of whom one died subsequently of multiorgan failure and two died of leukemia; one is still alive. A fifth patient had transient improvement in GvHD, which recurred when the corticosteroids were reduced. Three patients obtained no benefit from the procedure. We conclude that‘rescue’by transfusion of autologous or syngeneic nucleated cells may be valuable to treat severe refractory GvHD; the best approach to conditioning remains to be defined.Bone Marrow Transplantation (2004) 34, 995-998. doi:10.1038/sj.bmt.1704658 Published online 18 October 2004


Related Articles

  • Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation. Bashoura, L.; Gupta, S.; Jain, A.; Couriel, D. R.; Komanduri, K. V.; Eapen, G. A.; Safdar, A.; Broglio, K. R.; Adachi, R.; Dickey, B. F. // Bone Marrow Transplantation;Jan2008, Vol. 41 Issue 1, p63 

    Post transplantation constrictive bronchiolitis (PTCB) is the most common pulmonary complication among long-term survivors of allogeneic hematopoietic stem cell transplantation (HSCT). It is a late manifestation of GVHD. Its treatment with high-dose systemic corticosteroids and other...

  • Bone marrow and blood stem cell transplant survival rates equal, when donor is unrelated to patient.  // Biomedical Market Newsletter;12/14/2011, Vol. 21, p1 

    The article provides information on a study conducted by the Blood and Marrow Transplant Clinical Trials Network, a research collaboration of various institutes, according to which patients who receive bone marrow and blood stem cell transplant from a an unrelated donor are more likely to have...

  • Long-term survival after HLA-haploidentical SCT from noninherited maternal antigen-mismatched family donors: impact of chronic GVHD. Kanda, J.; Ichinohe, T.; Shimazaki, C.; Hamaguchi, M.; Watanabe, A.; Ishida, H.; Yoshihara, T.; Morimoto, A.; Uoshima, N.; Adachi, S.; Inukai, T.; Sawada, A.; Oka, K.; Itoh, M.; Hino, M.; Maruya, E.; Saji, H.; Uchiyama, T.; Kodera, Y. // Bone Marrow Transplantation;Sep2009, Vol. 44 Issue 5, p327 

    The article reports on the effectiveness of stem cell transplantation (SCT) from human leukocyte antigen-(HLA) haploidentical family donor as treatment of patients with high-risk hermatologic malignancies. It states that to minimize the risk of severe graft versus host disease (GVHD), most...

  • Management and Prevention of Graft-Versus-Host Disease Following Hematopoietic Stem Cell Transplantation in Pediatric Patients with Extracorporeal Photopheresis. Schneiderman, Jennifer // Asia Pacific Journal of Oncology & Hematology;2009, Vol. 1 Issue 2, p15 

    Allogeneic stem cell transplantation is curative for many patients, but carries significant risks and long term sequellae; acute and chronic graft-versus-host disease (GVHD) is a potentially debilitating or fatal complication and its therapies leave patients at significant risk for permanent...

  • Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Beri, R.; Chunduri, S.; Sweiss, K.; Peace, D. J.; Mactal-Haaf, C.; Dobogai, L. C.; Shord, S.; Quigley, J. G.; Chen, Y. H.; Mahmud, N.; Rondelli, D. // Bone Marrow Transplantation;Feb2010, Vol. 45 Issue 2, p249 

    A pretransplant test dose of i.v. BU was previously used in pediatric patients undergoing a reduced-intensity allogeneic hematopoietic SCT (HSCT). Here, we used a BU test dose in 23 adult patients who were not pancytopenic and underwent a myeloablative allogeneic HSCT prepared with fludarabine...

  • Protective Conditioning for Acute Graft-versus-Host Disease. Lowsky, Robert; Takahashi, Tsuyoshi; Liu, Yin Ping; Dejbakhsh-Jones, Sussan; Grumet, F. Carl; Shizuru, Judith A.; Laport, Ginna G.; Stockerl-Goldstein, Keith E.; Johnston, Laura J.; Hoppe, Richard T.; Bloch, Daniel A.; Blume, Karl G.; Negrin, Robert S.; Strober, Samuel // New England Journal of Medicine;9/29/2005, Vol. 353 Issue 13, p1321 

    Background: Conditioning with total lymphoid irradiation plus antithymocyte serum protects mice against acute graft-versus-host disease (GVHD) after hematopoietic-cell transplantation. We tested this strategy in humans. Methods: Thirty-seven patients with lymphoid malignant diseases or acute...

  • Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. van Besien, K; Devine, S; Wickrema, A; Jessop, E; Amin, K; Yassine, M; Maynard, V; Stock, W; Peace, D; Ravandi, F; Chen, Y-H; Cheung, T; Vijayakumar, S; Hoffman, R; Sosman, J // Bone Marrow Transplantation;Jul2003, Vol. 32 Issue 1, p9 

    Summary:Fludarabine, thiotepa and total body irradiation (TBI) has been used as conditioning in haplo-identical transplantation. We studied this conditioning regimen in adults undergoing matched sibling transplantation and alternative donor transplantation. A total of 30 consecutive patients...

  • Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bertz, H; Afting, M; Kreisel, W; Duffner, U; Greinwald, R; Finke, J // Bone Marrow Transplantation;12/1/99, Vol. 24 Issue 11, p1185 

    Therapy of acute intestinal GVHD is still one of the main challenges after allogeneic transplantation. Increasing systemic immunosuppression (IS) is the first choice and includes corticosteroids and lymphocyte antibodies, often associated with severe side-effects. In inflammatory bowel diseases...

  • Stem cell source-dependent reconstitution of FOXP3+ T cells after pediatric SCT and the association with allo-reactive disease. Reubsaet, L L; de Pagter, A P J; van Baarle, D; Keukens, L; Nanlohy, N; Sanders, E A M; Prakken, B J; Boelens, J J; de Kleer, I M // Bone Marrow Transplantation;Apr2013, Vol. 48 Issue 4, p502 

    In adult patients, regulatory CD4+FOXP3+ T cells are suggested to have a role in the control of allo-reactive disease after hematopoietic SCT (HSCT). We compared CD4+FOXP3+ T-cell reconstitution after unrelated cord blood (UCB), matched unrelated donor (MUD) and matched sibling donor (MSD) HSCT...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics